Skip to main content
PMC home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1996 Jul;27:S86–S88.

Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.

D J Chaplin 1, G R Pettit 1, C S Parkins 1, S A Hill 1
PMCID: PMC2150027  PMID: 8763854

Abstract

We have assessed the vascular effects of vinblastine and four other tubulin binding agents (dolastatin 10, dolastatin 15, combretastatin A1 and combretastatin A4), which are awaiting clinical evaluation. All five agents induce a reduction in tumour blood flow as measured by uptake of RbCI 24 h post drug administration. The degree of reduction ranged from 50% with combretastatin A1 to 90% with dolastatin 10. These reductions were similar to that seen with flavone acetic acid (FAA) and indicate that antivascular effects are a common feature of tubulin binding agents. We subsequently evaluated whether the blood flow reductions, induced by FAA and vinblastine, could be used to enhance the activity of the bioreductive drug tirapazamine. Since the kinetics and extent of blood flow reductions induced by the agents is comparable, similar therapeutic response was expected. Potentiation was only evident with FAA, indicating that this effect is not directly related to killing of hypoxic tumour cells induced as a consequence of blood flow reduction.

Full text

PDF
S86

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baguley B. C., Holdaway K. M., Thomsen L. L., Zhuang L., Zwi L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482–487. doi: 10.1016/0277-5379(91)90391-p. [DOI] [PubMed] [Google Scholar]
  2. Bai R. L., Pettit G. R., Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem. 1990 Oct 5;265(28):17141–17149. [PubMed] [Google Scholar]
  3. Bai R., Friedman S. J., Pettit G. R., Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol. 1992 Jun 23;43(12):2637–2645. doi: 10.1016/0006-2952(92)90153-a. [DOI] [PubMed] [Google Scholar]
  4. Bai R., Pettit G. R., Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990 Jun 15;39(12):1941–1949. doi: 10.1016/0006-2952(90)90613-p. [DOI] [PubMed] [Google Scholar]
  5. Bibby M. C., Double J. A., Loadman P. M., Duke C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst. 1989 Feb 1;81(3):216–220. doi: 10.1093/jnci/81.3.216. [DOI] [PubMed] [Google Scholar]
  6. Chaplin D. J., Horsman M. R. Tumor blood flow changes induced by chemical modifiers of radiation response. Int J Radiat Oncol Biol Phys. 1992;22(3):459–462. doi: 10.1016/0360-3016(92)90853-a. [DOI] [PubMed] [Google Scholar]
  7. Cliffe S., Taylor M. L., Rutland M., Baguley B. C., Hill R. P., Wilson W. R. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):373–377. doi: 10.1016/0360-3016(94)90292-5. [DOI] [PubMed] [Google Scholar]
  8. Dorie M. J., Brown J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 1993 Oct 1;53(19):4633–4636. [PubMed] [Google Scholar]
  9. Edwards H. S., Bremner J. C., Stratford I. J. Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):373–377. doi: 10.1080/09553009114552181. [DOI] [PubMed] [Google Scholar]
  10. Hill S. A., Lonergan S. J., Denekamp J., Chaplin D. J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer. 1993;29A(9):1320–1324. doi: 10.1016/0959-8049(93)90082-q. [DOI] [PubMed] [Google Scholar]
  11. Hill S. A., Sampson L. E., Chaplin D. J. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer. 1995 Sep 27;63(1):119–123. doi: 10.1002/ijc.2910630121. [DOI] [PubMed] [Google Scholar]
  12. Kallinowski F., Schaefer C., Tyler G., Vaupel P. In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer. 1989 Oct;60(4):555–560. doi: 10.1038/bjc.1989.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mahadevan V., Malik S. T., Meager A., Fiers W., Lewis G. P., Hart I. R. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res. 1990 Sep 1;50(17):5537–5542. [PubMed] [Google Scholar]
  14. Pettit G. R., Singh S. B., Boyd M. R., Hamel E., Pettit R. K., Schmidt J. M., Hogan F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) J Med Chem. 1995 May 12;38(10):1666–1672. doi: 10.1021/jm00010a011. [DOI] [PubMed] [Google Scholar]
  15. Pettit G. R., Singh S. B., Hamel E., Lin C. M., Alberts D. S., Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989 Feb 15;45(2):209–211. doi: 10.1007/BF01954881. [DOI] [PubMed] [Google Scholar]
  16. Pettit G. R., Singh S. B., Niven M. L., Hamel E., Schmidt J. M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod. 1987 Jan-Feb;50(1):119–131. doi: 10.1021/np50049a016. [DOI] [PubMed] [Google Scholar]
  17. SAPIRSTEIN L. A. Regional blood flow by fractional distribution of indicators. Am J Physiol. 1958 Apr;193(1):161–168. doi: 10.1152/ajplegacy.1958.193.1.161. [DOI] [PubMed] [Google Scholar]
  18. Sun J. R., Brown J. M. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res. 1989 Oct 15;49(20):5664–5670. [PubMed] [Google Scholar]
  19. Veszelovszky E., Thomsen L. L., Li Z., Baguley B. C. Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis. Eur J Cancer. 1993;29A(3):404–408. doi: 10.1016/0959-8049(93)90396-w. [DOI] [PubMed] [Google Scholar]
  20. Woods J. A., Hadfield J. A., Pettit G. R., Fox B. W., McGown A. T. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer. 1995 Apr;71(4):705–711. doi: 10.1038/bjc.1995.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Zwi L. J., Baguley B. C., Gavin J. B., Wilson W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst. 1989 Jul 5;81(13):1005–1013. doi: 10.1093/jnci/81.13.1005. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES